AT-HOME BLOOD COLLECTION
Making blood collection as easy as a COVID self-test
C2K is the low-cost infrastructure layer for at-home blood collection — unlocking laboratory-grade blood testing from home at a fraction of today's cost.
500–1000 µL capillary blood
>80% user acceptance
<€1 target unit cost
Patent filed US · EU · PCT
Red Dot Award winner
WHY C2K
The simplicity of a finger prick, the reliability labs require
A purely mechanical device that drops straight into existing laboratory workflows — no proprietary kit, no electronics.
Standard consumables
Works with standard lancets and standard specimen tubes — no proprietary consumables to source or stock.
Lab-grade volume
Reliably collects 500–1000 µL of capillary blood — the volume real laboratory assays need.
Radically low cost
Gravity-driven, with no electronics and a target manufacturing cost under €1 at scale.
Built for adoption
Simple finger placement, >80% user acceptance, and HIV, syphilis & HCV workflows already demonstrated.
CLINICAL RESULTS
Validated in an 80-person study
Real-world performance from lay users collecting their own capillary blood at home.
~700 µL
average volume collected
750 µL
median volume collected
74%
of users collected >400 µL
>80%
user acceptance
HIV
Syphilis
HCV
diagnostic workflows demonstrated — samples stable up to 7 days at 30 °C for STI testing.
TEAM
Diagnostics, product & commercialization veterans
Backed by 1200+ products developed through Voxdale and deep diagnostics expertise from ITM.
Tim Dieryckx
Interim CEO
CEO of Voxdale; engineer with an Executive MBA and a decade scaling complex hardware ventures.
Koen Beyers
Founder
Founder of Voxdale and serial MedTech inventor (Novosanis, Idevax).
Irith De Baetselier
Medical & Clinical Lead
MD/PhD; coordinator of Belgium's National Reference Centre for STIs at ITM.
Tom Dewaele
Head of Product
Leads design and user experience at Voxdale, with a usability-first development approach.
Bert Bruggeman
Chairman
30+ years in product & operations; ex-Tesla and IMEC; Chairman of The Ocean Cleanup.
Vanessa Vankerckhoven
Board Member
PhD; co-founder and former CEO of Novosanis (acquired by OraSure); CEO of Idevax.
ABOUT & FAQ
About C2K
C2K is a low-cost, at-home blood collection device from Voxdale and the Institute of Tropical Medicine (ITM) — a Red Dot Award winner 2026 — that captures laboratory-grade capillary blood using standard lancets and standard specimen tubes.
What is C2K?
C2K is a low-cost, at-home blood collection device that lets people collect 500–1000 µL of capillary blood themselves using a standard lancet and a standard specimen tube, giving laboratories the sample quality they need without a clinic visit.
How does C2K collect blood at home?
After a simple finger prick with a standard lancet, the user places their finger on the C2K cap and gravity guides the blood into a standard specimen tube. There are no electronics and no proprietary consumables.
How much blood does C2K collect?
In an 80-person study, C2K collected on average about 700 µL of capillary blood (median 750 µL), with 74 percent of users collecting more than 400 µL and over 80 percent user acceptance.
What can C2K be used for?
C2K supports remote and decentralized diagnostics, with HIV, syphilis and HCV workflows already demonstrated, across clinical trials, laboratories, telehealth, and chronic-disease and STI monitoring. STI samples stay stable up to 7 days at 30 °C.
How is C2K different from Tasso or TAP?
Unlike most home-collection devices, C2K works with standard specimen tubes and standard lancets instead of proprietary consumables, captures a large 500–1000 µL volume, uses no electronics, and targets a sub-1 euro manufacturing cost, making it lab-compatible and far cheaper.
Who makes C2K?
C2K is developed by the Belgian product-development firm Voxdale together with the Institute of Tropical Medicine (ITM). The device is a Red Dot Award winner 2026.
PARTNERS & INVESTORS
Let's make remote diagnostics work
Whether you run clinical trials, a laboratory or a telehealth platform —or you're an investor backing decentralised diagnostics — we'd love to talk.
or email us directly at